ID: MRFR/Pharma/1873-HCR | February 2021 | Region: Global | 90 pages
Conjunctivitis Drugs Market is expected to register 3.1% CAGR during the forecast period of 2019 to 2025 and will be valued at USD 1.18 Billion in 2025.
Conjunctivitis is commonly known as “pink eye” is an inflammation or swelling of the conjunctiva.
The prevalence of conjunctivitis or pink eye is increasing globally, fueling market growth. Conjunctivitis drugs are used for the treatment of conjunctivitis. There are various types of conjunctivitis including bacterial, allergic, viral, and chemical. Conjunctivitis affects millions of people and imposes economic and social burdens. In the US, it is estimated that acute conjunctivitis affects about 6 million people annually. The major factors influencing the growth of the market include increasing prevalence of conjunctivitis. Bacterial conjunctivitis is the second most common cause and is responsible for the majority 50–75% of the cases in children. It is found that primary care physicians are the first point of treatment for most of the conjunctivitis patients rather than eye care professionals. About 1% of the visits for primary care offices in the US are associated with conjunctivitis. Moreover, a rise in hygiene and awareness, growing expenditure on health, greater exposure to allergens and infective agents, and the contagious nature of the disease are expected to drive the growth of the market.
Furthermore, factors such as appropriate diagnosis for viral conjunctivitis and limited awareness regarding advanced technologies are hampering the growth of the global market.
The Conjunctivitis Drugs Market is segmented based on conjunctivitis type, drug class, route of administration, end users, and region.
The conjunctivitis drugs market, by conjunctivitis type, is segmented into bacterial, allergic, viral, and chemical. The bacterial segment is further classified into hyperacute bacterial conjunctivitis, acute bacterial conjunctivitis, and chronic bacterial conjunctivitis. The allergic segment is further classified into atopic keratoconjunctivitis, simple allergic conjunctivitis, seasonal conjunctivitis, vernal conjunctivitis, and giant papillary conjunctivitis.
Viral conjunctivitis was the largest segment of the market, as viruses cause up to 80% of all cases of acute conjunctivitis. Viral conjunctivitis is more prevalent in summer and is the most common cause of infectious conjunctivitis across the globe. Furthermore, bacterial conjunctivitis expected to be the fastest-growing segment, as about 1.8% to 5.6% of all acute conjunctivitis is caused by chlamydia. Allergic conjunctivitis affects about 40 percent of the population, but only a small number of individuals pursue medical care.
Chemical conjunctivitis accounted for the least conjunctivitis drugs market share. Chemical conjunctivitis represents between 11.5–22.1% of ocular trauma.
Based on drug class, the conjunctivitis drugs market is segmented into antibiotics, mast cell stabilizers, steroids, and others
Based on the administration, the conjunctivitis drugs market is segmented into topical, oral, intra-vitreal, and others. The topical antibiotics segment accounted for the major market share as these products are most effective in reducing the period of conjunctivitis.
Based on end user, the conjunctivitis drugs market is segmented into hospitals and clinics and specialty centers.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The conjunctivitis drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European conjunctivitis drug market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The conjunctivitis drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The conjunctivitis drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.
Some of the key players operating in the conjunctivitis drugs global market are Akorn Pharmaceuticals (US), Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch & Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).
Regional Market Summary
Global Conjunctivitis Drugs Market Share (%), by Region, 2018
Sources: MRFR Analysis
The Americas dominated the global conjunctivitis drugs market owing to the increasing awareness among the people, the presence of major manufacturers, the growing adoption of online purchasing medicine increasing prevalence of conjunctivitis and others. According to a study it was found that about 3 million cases conjunctivitis occurs in the US annually.
In 2018, Europe was the second-largest regional market. However, Asia-Pacific is expected to grow with the fastest growth rate throughout the forecast period due to the increasing investments by market players in the region. On the other hand, the Middle East & Africa holds the least share in the global conjunctivitis drugs market due to the low economic development, especially in Africa.
Global Conjunctivitis Drugs Market, by Conjunctivitis Type
Global Conjunctivitis Drugs Market, by Drug Class
Global Conjunctivitis Drugs Market, by Route of Administration
Global Conjunctivitis Drugs Market, by End Users
Global Conjunctivitis Drugs Market, by Region
|Market Size||2025: USD 1.18 Billion|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Conjunctivitis Type, Drug Class, End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Akorn Pharmaceuticals (US), Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Bausch & Lomb (US), Actavis Plc (US), Pfizer Inc (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada).|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
The Global Conjunctivitis Drugs Market is projected grow at approximately 3.1% CAGR during the assessment period (2019-2025).
The valuation of the Global Conjunctivitis Drugs Market is estimated to increase to USD 1.18 BN by the end of 2025.
Increasing prevalence of bacterial conjunctivitis, growing expenditure on health, and greater exposure to allergens and infective agents are the major tailwinds pushing the growth of the Global Conjunctivitis Drugs Market
North America holds the largest share in the Global Conjunctivitis Drugs Market, followed by Europe and the Asia Pacific, respectively.
Alcon/ Novartis AG (Switzerland), Allergan Plc (Ireland), Actavis Plc (US), Akorn Pharmaceuticals (US), Bausch & Lomb (US), Pfizer Inc. (US), Merck & Co. Inc. (US), Lupin Limited (India), and Valeant Pharmaceuticals (Canada), are some of the major players operating in the conjunctivitis drugs market.